ClinicalTrials.gg
TerminatedNCT04609397Updated Jun 21, 2022

A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

A Phase 2 interventional study of Hemay005 and Hemay005 in Behçet Disease, sponsored by Tianjin Hemay Pharmaceutical Co., Ltd. Terminated at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Tianjin Hemay Pharmaceutical Co., Ltd · Phase 2, Interventional, and Prevention

Why this study was terminated
The study purpose has been achieved

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Behcet Syndrome with a site in China — 7 open to participants now, 7 under way, 1 of them phase 3. Behcet Syndrome · China.

Enrollment
2nd of 13
89 · median 50
Started
2020
with 2 others
Phase 2
11 of 16
4 open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Tianjin Hemay Pharmaceutical Co., Ltd

Among the 16 studies in Behcet Syndrome with a site in China, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2020, is one of 11 in phase 2, and was the 6th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

7 of the 16 studies in Behcet Syndrome with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Behcet Syndrome with a site in China, or all of them as a file.
02

Study summary

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 12weeks and a follow up phase for 4weeks.

Read the detailed description

this study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study to evaluate Hemay005 efficacy and safety of the treatment of patients with Behçet Disease(BD). Around 252 subjects will be randomized into this study.

The whole study will including 4 phases that a screening phase, core-treatment phase(12weeks), extended-treatment phase (12weeks) and follow-up phase(4 weeks).

Screening: All subjects will undergo a screening period of up to 6 weeks prior to baseline visit (visit 2, day of randomization, Day0).

Core treatment phase: eligible BD patients will randomly assigned to Hemay005 high-dose group, Hemay005 low-dose group, placebo (core treatment phase) + Hemay005 high-dose group (extended treatment phase), or placebo (core treatment phase) + Hemay005 low-dose group (extended treatment phase). During the core-treatment period, hemay005 will be administered twice daily for 12 weeks. The randomization was stratified to minimize the imbalance between treatment groups.

Extended treatment phase: Subjects in the high-dose and low-dose groups during the extended treatment period will still given the dose of core-treatment phase for 12 weeks. Subjects who received placebo during the core treatment will assigned to either a high-dose group or a low-dose group according the allocation at visit 2 until 12 weeks after. During this period, the subject and investigator are remain blind at this stage.

Follow up phase: Subjects in the study (also including those who withdraw from treatment for any reason) will have another follow up for 4 weeks after the end of the last administration.

03

Conditions studied

  • Behçet Disease

Browse trials for

Keywords

  • Behçet Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Understand and voluntarily sign an form prior to any study related assessments/procedures being conducted.
  • 2.Male and female subjects 18\~75(inclusive) years of age at the time of signing the informed consent form.
  • 3.Diagnosed with Behçet's disease meeting the International Study Group (ISG) criteria (2013).
  • 4.Subjects must have at least 2 oral ulcers at V1, and:

    1. at least 2 oral ulcers at V2 if V2 occurs at least 14 days after Visit 1, OR
    2. at least 3 oral ulcers at V2 if V2 occurs at least 0\~42 days after Visit 1.
    1. According to the site investigator judgement, subject is suitable to the systemic but not topical treatment of oral ulcer considering the severity and affected area of the disease OR the oral ulcer cannot be well controlled by topical treatment and have to take the systemic treatment.
  • 6.All females of (FCBP) and male subjects who did not receive the vasectomy must take effective measures.

Exclusion criteria

Exclusion Criteria:

  • 1.subject has the BD related major organ activity lesions requiring therapy- pulmonary, vascular, gastrointestinal, and central nervous systems (eg, meningoencephalitis) manifestations, etc. However:

    1. Previous major organ involvement is allowed if it occurred at least one years prior to screening visit and is not active at time of enrollment.
    2. Subjects with BD-related arthritis and BD-skin manifestations are also allowed
    1. Any heart disease (e.g., but not limited to unstable ischemic heart disease, (NYHA) class III / IV left ventricular failure, or myocardial infarction) or clinically significant 12 lead abnormalities found during screening, which, according to the investigator's judgment, may put the patient at safety risk or may interfere with the investigator;
    1. subjects who current receiving immunotherapy including:

      1. 7 days prior to Visit 2 (randomization) for colchicine.
      2. 10 days prior to Visit 2 (randomization) for azathioprine, mycophenolate mofetil, baricitinib or Tofacitinib.
      3. 4 weeks prior to visit 2(randomization) for cyclosporin, methotrexate, cyclophosphamide, thalidomide, and dapsone.
      4. At least 5 terminal half-lives for all biologics, including,within:

        1. Four weeks prior to visit 2(randomization) for etanercept.
        2. Eight weeks prior to visit 2(randomization) for infliximab.
        3. Ten weeks prior to visit 2(randomization) for adalimumab, golimumab, abatacept, and tocilizumab.
        4. Six months prior to visit 2(randomization) for secukinumab.
  • 4.Having received intra-articular or parenteral within 6 weeks (42 days) prior to Visit 2.
  • 5.Laboratory examination of V1 in screening period:

    1. ≤ 85g / L;
    2. The white blood cell (WBC) count was less than 3.0 × 10\^9 / L or more than 14 × 10\^9 / L;
    3. \< 100 × 10\^9 / L;
    4. Serum creatinine > 1.5mg/dl (> 132.6 μ mol / L);
    5. Total > 2.0 mg / dl (> 34.2 μ mol / L);
    6. The (AST) and Alanine aminotransferase (ALT) were higher than 1.5 times of the value.
  • 6.subjects who received strong cytochrome P450 enzyme inducer within 4 weeks prior to visit2.
  • 7.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, and C and herpes zoster, histoplasmosis, coccidiomycosis, but excluding onychomycosis) , judged by investigator,may put the patient at safety risk.
  • 8.Clinically significant abnormality on chest radiograph or CT,judged by investigator, may put the patient at safety risk.
  • 9.History of transplantation and immunodeficiency disease, including those subject has a positive test for (HIV).
  • 10.subject who use of any products of clinical trials within 4 weeks or within 5 pharmacokinetic/pharmacodynamic half-lives prior to randomization, whichever is longer;
  • 11.known to be allergic or allergic to the investigational products or ingredients;
  • 12.History of alcohol or drug abuse, or a history of mental illness;
  • 13.Subjects with severe, progressive, or uncontrolled disease, judged by the investigator, who maybe at risk if participate this study or those subjects whose participation may influence the interpretation of study results.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Hemay005 high dose group

    In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.

    Drug: Hemay005

  • Experimental
    Hemay005 lower dose group

    In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.

    Drug: Hemay005

  • Placebo comparator
    Placebo

    In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.

    Drug: Hemay005 · Other: Placebo

Interventions

  • Hemay005 tables 60mg bid p.o;

    Also known as: Phosphodiesterase 4 (PDE4) inhibitors

  • Hemay005 tables 45mg bid p.o

    Also known as: Phosphodiesterase 4 (PDE4) inhibitors

  • OtherPlacebo

    placebo to Hemay005 tables bid p.o

06

What researchers measure

Primary outcomes

  1. to evaluate the efficacy of Hemay005 in the treatment of Behçet's disease.

    Area under the curve (AUC) for the number of oral ulcers from baseline through Week 12

    Time frame: week 12

Secondary outcomes

  1. Proportion of subjects achieving an oral ulcer complete response

    Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) by Week 6 after dosing, and who remain oral ulcer free for at least 6 additional weeks during the Treatment Phase

    Time frame: week 6

  2. Complete response rate for oral ulcers

    Complete response rate for oral ulcers at day 3, day 7 and Week 12

    Time frame: day 3, day 7 and week12

  3. change of the pain evaluation of oral ulcers as measured by Visual analogue scale(VAS)(From 0-100, the higher score means the worse outcome)

    Change from baseline in the pain of oral ulcers as measured by VAS at Week 12

    Time frame: week12

  4. change of the number of oral ulcers

    Change from baseline in the number of oral ulcers at Week 12

    Time frame: week12

  5. Time to oral ulcer resolution

    Time to oral ulcer resolution (complete response) that the first instance when a subject has a complete response during the core-Treatment Phase

    Time frame: week12

  6. Proportion of subjects achieving an oral ulcer complete response in the core-treatment phase

    Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) and who remain oral ulcer free during the core-treatment Phase

    Time frame: week12

  7. Number of oral ulcers who has a reappearance during the core-treatment phase

    Number of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase

    Time frame: week12

  8. Time to oral ulcer reappearance during the core-treatment

    Time to recurrence of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase

    Time frame: week12

  9. change of the total score of Physician's Global Assessment(PGA)

    change from baseline in the total score of the PGA of skin lesions of BD at week 12 in those subjects who had at baseline

    Time frame: week12

  10. change of BD Current Activity Form(BDCAF)

    change from baseline in the total score of the BDCAF questionnaire at week 12

    Time frame: week12

  11. change of Multi-Dimensional Health Assessment Questionnaire (MDHAQ)

    change from baseline in the total score of the MDHAQ questionnaire at week 12

    Time frame: week12

  12. change of short from health survey(SF-36)

    change from baseline in the total score of the SF-36 questionnaire at week 12

    Time frame: week12

  13. Complete response rate for genital ulcers

    Complete response rate for genital ulcers at Week 12 for subjects who had genital ulcers at Baseline

    Time frame: week12

  14. change of the pain evaluation of genital ulcers

    Change from baseline in the pain of genital ulcers as measured by VAS at Week 12

    Time frame: week12

  15. Change of the Behçet's syndrome activity score(BSAS) score

    Change from Baseline in BSAS score at Week 12

    Time frame: week12

  16. Maximum Plasma Concentration (Cmax)

    the population pharmacokinetic (popPK) characteristics Cmax of Hemay005 in BD patients

    Time frame: week24

  17. Minimum Plasma Concentration (Cmin)

    the population pharmacokinetic (popPK) characteristics Cmin of Hemay005 in BD patients

    Time frame: week24

  18. Time to peak (Tmax)

    the population pharmacokinetic (popPK) characteristics Tmax of Hemay005 in BD patients

    Time frame: week24

  19. Elimination half-life (T1/2)

    the population pharmacokinetic (popPK) characteristics T1/2 of Hemay005 in BD patients

    Time frame: week24

  20. Area under drug time curve (AUC)

    the population pharmacokinetic (popPK) characteristics AUC of Hemay005 in BD patients

    Time frame: week24

  21. Clearance (Cl)

    the population pharmacokinetic (popPK) characteristics Cl of Hemay005 in BD patients

    Time frame: week24

  22. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

    the Incidence of Treatment-Emergent Adverse Events of Hemay005 in BD patients with different dosing group

    Time frame: week24

  23. the number of subjects who terminated hemay005 prematurely due to adverse events (AE) [Safety and Tolerability])

    the number of subjects who terminated hemay005 prematurely due to adverse events (AE) in BD patients with different dosing group

    Time frame: week24

07

Study locations

31 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Anhui provincial hospital
    Hefei, Anhui, China
  • Beijing hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Peking University First Hospital
    Beijing, Beijing, China
  • Peking University People's Hospital
    Beijing, Beijing, China
  • Peking University Shougang Hospital
    Beijing, Beijing, China
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • The University of Hong Kong-Shenzhen Hospital
    Shenzhen, Guangdong, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of science and technology
    Baotou, Inner Mongolia, China
  • Jiangsu Provincial Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • Jiu Jiang NO.1 people's Hospital
    Jiujiang, Jiangxi, China
  • Jiangxi Pingxiang people's Hospital
    Pingxiang, Jiangxi, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin, China
  • Jilin Provincial People's Hospital
    Changchun, Jilin, China
  • Linyi people's Hospital
    Linyi, Shandong, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Tongji Hospital Of Tongji University Tang Jianping
    Shanghai, Shanghai, China
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of Chengdu Medical College
    Chengdu, Sichuan, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Ürümqi, Xinjiang, China
  • First Affiliated Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Apr 2022, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Oct 30, 2020
StartActual
Nov 30, 2020
Primary completionActual
Apr 30, 2022
CompletionActual
Apr 30, 2022
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04609397
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Nov 30, 2020
Primary completion
Apr 30, 2022
Completion
Apr 30, 2022
Last update
Jun 21, 2022

Study contacts

zhanguo Li, Doctor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion